Ensifentrine

iStock, SvetaZi Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiry of its blockbuster’s patents. Continuing its campaign to grow its pipeline amid Keytruda’s looming loss of exclusivity, Merck has moved to absorb Terns Pharmaceuticals and its mid-stage leukemia drug, an asset that analysts say could offer the pharma a multi-billion revenue opportunity. The Terns buyout is “one of the best deals [Merck] has made since its spree began ahead of the Keytruda LOE,” analysts at BMO Capital Markets wrote in a note to investors on Tuesday evening, responding to swirling reports that the pharma was in late-stage talks with the California biotech. The rumor was first broken by the Financial Times . BMO called Terns’ lead asset, the oral tyrosine kinase inhibitor TERN-701, a “differentiated agent” in chronic myeloid leukemia (CML), adding that it has elicited robust major molecular responses in a highly refractory patient population. TERN-701, the analysts estimated, “offers an unadjusted peak sales of >$4B, meaningfully contributing to Merck’s plans to patch its Keytruda LOE hole at the end of the decade.” Patents 5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of the industry’s top-performers are losing key market protections. Some companies are more prepared than others. February 19, 2025 · 10 min read · Tristan Manalac Read more Under the terms of Wednesday’s acquisition agreement, Merck will purchase all of Terns’ outstanding shares for $53 a pop—a 31% premium to the biotech’s average stock price over the preceding 60 days—resulting in a roughly $6.7 billion equity value. The deal has been approved by the boards of directors of both companies and the parties expect to complete the transaction in the second quarter. The Terns takeover further diversifies and strengthens our position in oncology as we continue to look for opportunities to broaden our portfolio into other therapeutic areas,” Merck CEO Robert Davis said in a statement on Wednesday. In particular, the agreement “builds on our growing presence in hematology,” he added, calling TERN-701 a “potential best-in-class candidate” for CML. Taken orally, TERN-701 is an allosteric inhibitor of BCR-ABL1, a protein that arises from an abnormal genetic fusion that is the hallmark of CML. Phase 1 data revealed last December showed an overall major molecular response rate as high as 75% at 24 weeks , with a tolerability pro supported daily dosing. “Unprecedented remains the only suitable adjective to describe the compound’s clinical profile,” William Blair analysts wrote in a Dec. 9 note, adding that TERN-701 “is on track to challenge Scemblix’s dominance and disrupt the treatment paradigm of CML.” Owned by Novartis, Scemblix was first approved in October 2021 for the same indication. The drug made $1.285 billion last year . William Blair analysts value TERN-701 so highly that they questioned Merck’s offer, saying in a note Wednesday morning after the deal was announced that it “does not fully capture the potential of TERN-701.” “We believe another bidder could emerge with a more attractive offer,” the firm added. RBC Capital Markets agreed. “We view the decision to acquire TERN before full dose escalation as a sign of high confidence in the asset,” the analysts wrote in their own note on Wednesday. They added, however, that Merck’s price “opens the door for competing bids from other potential acquirers where the deal makes strategic sense,” such as AbbVie or Bristol Myers Squibb. Mergers & acquisitions Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality and a declining stock of available biotechs with mature assets. March 11, 2026 · 5 min read · Annalee Armstrong Read more Key protections for Keytruda, Merck’s mega-blockbuster PD-1 inhibitor, are set to expire in 2028 , after which the pharma can expect to cede some of the market to biosimilars. In addition to a recent spate of deals, the pharma has is also working to maintain its earnings through the reformulation of Keytruda into a subcutaneous injection, which the FDA cleared in September last year . Merck is marketing the product as Keytruda Qlex. Still, the pharma has been an aggressive dealmaker over the past year, betting billions to enrich not only its late-stage pipeline but also its commercial portfolio. In November 2025, for instance, Merck swallowed Cidara Therapeutics for $9.2 billion , gaining a Phase 3 antiviral drug. A few months earlier, the pharma dropped $10 billion to acquire Verona Pharma and the FDA-approved Ohtuvayre for chronic obstructive pulmonary disease. For Terns, the deal represents a triumphant exit after refocusing its attention last August on TERN-701. Once a rising star in obesity and the MASH space, Terns announced at that time that it would look to partner off a clutch of metabolic assets amid an oversaturated market in the obesity realm. Terns was one of several companies that BioSpace highlighted as likely M&A targets for Big Pharma this year. Earnings Keytruda Hangs On to Best Seller Crown as GLP-1s Gain Ground Merck’s Keytruda will soon lose exclusivity, just as weight-loss giants Eli Lilly and Novo Nordisk press in with their blockbuster GLP-1s. March 4, 2026 · 9 min read · Tristan Manalac Read more

博鳌亚洲论坛2026年年会 于3月24日至27日召开 全球的目光聚焦海南博鳌 而作为琼海的医疗康养特色名片 乐城先行区也攒了一波惊喜！ 除了会场的头脑风暴 不妨抽点时间来乐城 感受医疗旅游的别样打开方式 探秘创新药械展，解锁前沿医疗科技新体验 在博鳌乐城“永不落幕”国际创新药械展，近距离接触国际前沿的创新医疗产品。 作为全国唯一汇集全球创新药品与尖端医疗器械的长期展示馆，这里汇聚了来自16个国家80多家国际创新药械企业的近千种最先进药械产品。 全球体积最小的心脏起搏器、大机器人一样的最新“磁共振”、“放射学界的学霸”深度天眼CT……不用远赴国外，就能沉浸式了解全球顶尖医疗技术。 ⭐门票：凭身份证免费入馆观展 ⭐地址：海南省琼海市康祥路与乐天路交叉口东南方向135米 “特许医疗”同步全球创新产品，守护你我健康 乐城先行区依托“特许医疗”政策优势，重点打造肿瘤诊治、慢病管理、亚健康调理、医美抗衰、眼科诊疗等核心特色专科集群，为广大国内外游客提供国际领先的高品质、个性化医疗旅游服务。 截至目前，乐城已引进使用未在国内上市的国外创新药械超550种，惠及患者24余万人次；15款特殊食品获批，满足不同群体的健康需求。2025年接待医疗旅游86.53万人次，同比增长109.2%，全年接待入境医疗旅游9344人次，客源覆盖印度尼西亚、马来西亚、老挝、加拿大等14个周边国家和地区。 ↓点击查看外国友人在乐城体验医疗旅游↓ 部分特色项目/产品 1 肿瘤诊治 硼中子俘获疗法用中子照射装置——肿瘤治疗的“定向狙击手” 硼中子俘获疗法是治疗不可手术复发性局部晚期头颈部恶性肿瘤的有效技术手段。具有高度靶向精准且副作用低的特点。2026年3月，乐城鹏博（海南）硼中子医院成功完成国内首台获批BNCT治疗系统首次应用，为一位来自河南的晚期复发性舌癌患者带去治疗新希望。 相关阅读：重磅突破！乐城鹏博（海南）硼中子医院成功完成国内首台获批BNCT治疗系统首次应用 2 慢病管理 ①中国大陆首款糖尿病特医食品乐奔拓 乐奔拓专膳特殊医学用途糖尿病全营养配方食品专为糖尿病患者的营养需求精准定制。在控糖的同时助力肠道健康与体力维持。 相关阅读：既要美味也要健康！过年乐城教你这样吃，血糖稳稳不“翻车” ②全球首创慢阻肺维持治疗药物Ensifentrine（恩司芬群） Ensifentrine（恩司芬群）是一款全球首创的吸入型磷酸二酯酶3、4双靶点抑制剂（PDE3 & PDE4），双重抑制机理使其能够凭借单个化合物同时实现支气管扩张以及抗炎活性，适用于成人慢性阻塞性肺疾病患者的维持治疗。 相关阅读：全国约1亿人受这种病困扰！乐城已引进全球首创疗法 ③1年2次长效“降脂针”Inclisiran（英克西兰） 作为首创用于降低低密度脂蛋白胆固醇（LDL-C）的小干扰核酸（siRNA）疗法，Inclisiran于2020年12月在欧盟获批用于治疗成人高胆固醇血症及混合性血脂异常。其创新的小干扰核酸作用机制使患者每年仅需两次皮下注射即可获得降脂疗效，被称为心血管领域“疫苗”。 3 亚健康调理 ①中医疗愈 园区多家医疗机构提供中药内服外敷、针刺、拔罐、艾灸、沉香古方等多种传统中医疗法，辨证治疗疑难杂症及亚健康状态。 △乐城特色中医理疗吸引海外华人专程而来△ ②䓲能牌辅酶Q10姜黄软胶囊 具有抗氧化的保健功能，适用人群为中老年人，由天然保健品研发、生产与全球销售的领先企业墨尔本品牌有限公司研发。 相关阅读：乐城进口保健食品再扩容！䓲能牌辅酶Q10姜黄软胶囊获批 4 皮肤健康与医疗美容 ①首款白癜风复色疗法芦可替尼乳膏 芦可替尼乳膏是一种小分子靶向药，是美国食品和药物监督管理局（FDA）以及欧洲药品管理局（EMA）批准的首个也是唯一一个局部JAK抑制剂白癜风复色产品，用于12岁及以上青少年和成人患者伴面部受累的非节段型白癜风的局部治疗。 相关阅读：乐城真研试点新成果！白癜风创新药磷酸芦可替尼乳膏获批在中国上市 ②V-OLET去氧胆酸注射液 韩国首个批准上市的脱氧胆酸注射液新药。通过V-OLET治疗时，无需手术即可改善双下巴脂肪堆积，紧致肌肤和清晰下颌线。 相关阅读：摆脱双下巴烦恼！乐城这家医院又达成一个“变美”小目标！ 特色康养游带你边玩边养，把健康融入旅途 为满足不同群体的健康需求，乐城创新推出多条医疗旅游线路，将高端医疗服务与琼海的度假资源相融合，打造独一无二的健康旅行。 △上海劳模团在乐城打开医疗旅游新姿势△ 乐城医疗旅游线路推荐 < > 左右滑动查看更多 共赴“乐城春养生”健康之约，给身体放个春日小假 眼下，“乐城春养生”健康节活动正在火热进行中。不论你是参会嘉宾、媒体朋友，还是本地居民、远道而来的游客，都欢迎来凑个热闹。不用专门安排，也不用复杂准备，趁春光正好，给自己安排一次轻松的健康体验吧！ 打卡集章得养生好礼 玩转养生市集 △点击查看“乐城春养生”活动攻略△ 相关阅读： 听说乐城养生最近很“火”？你关心的义诊、免费项目，都在这儿了！ 来都来了 不妨把健康也安排上！ 看一场前沿药械展 做一次身体扫描 或是来一趟康养之旅 这个春天 我们在博鳌乐城等你！ “乐”享世界医疗，“城”就健康梦想 更多相关信息 请关注“乐城发布”公众号 咨询电话：4000-118-118 审核：何颖 编辑：林春茹